Navigation Links
Ambry Genetics Announces the Addition of Array CGH Services Through Partnership With Baylor College of Medicine
Date:5/5/2009

ALISO VIEJO, Calif., May 5 /PRNewswire/ -- Ambry Genetics Corp. announces the implementation of Comparative Genomic Hybridization (CGH) using oligonucleotide arrays through a partnership with Baylor College of Medicine. Large chromosomal abnormalities that are associated with over 270 genetic syndromes can be easily identified via analysis of each 105K whole genome and mitochondrial array. The partnership with Baylor College of Medicine equips Ambry with an extensive library as a reference, as well as expert support for cytogenetics.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090428/LA06744LOGO)

Ambry's CSO, Anja Kammesheidt states, "The oligonucleotide array was developed at Baylor College of Medicine and has proven to be an essential diagnostic tool. We are extremely pleased to be able to offer these same services now directly through our laboratory. Array CGH is becoming an integral part in any comprehensive genetic assessment."

The recent advancements in DNA microarrays are revolutionizing diagnostics by providing the ability to perform targeted and genome-wide studies (GWAS). Array CGH is used to detect genome-wide chromosomal imbalances with a single laboratory test consisting of multiple probes targeting virtually all disorders detected by traditional cytogenetics and fluorescent in situ hybridization (FISH). Array CGH is designed for patients with unexplained developmental delay, autism spectrum disorders, dysmorphic features, unexplained mental retardation, and/or multiple congenital anomalies. Each array contains 105K oligonucleotide probes, spaced at 30K through the genome with increased density at disease loci. Abnormalities are confirmed with other methods such as traditional FISH or MLPA. The test offers high resolution, sensitivity, enhanced clinical detection rates, and greater accuracy in interpretation because of high coverage of clinically significant areas.

About Ambry Genetics

Ambry Genetics is a CAP-accredited, CLIA-certified commercial clinical laboratory headquartered in Aliso Viejo, California. Since the company's inception in 2000, it has become a leader in providing genetic services focused on clinical diagnostics, pharmacogenomics and research support. Ambry has built a solid reputation for unparalleled service, and has been at the forefront of applying new technologies to the clinical molecular diagnostics market and advancements in disease research. To learn more about testing and services available through Ambry, visit www.ambrygen.com.

This report contains forward-looking statements about the Company's future plans, strategies, objectives, goals and expectations, including projections, estimates, prospects, returns and performance of the Company. Forward-looking statements can be identified by the use of forward-looking terminology such as "may," "will," "should," "expect," "anticipate," "estimate," "intend," "continue," or "believe" or the negatives thereof or other variations thereof or comparable terminology. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. In light of the significant uncertainties inherent in the forward-looking statements made in this report the inclusion of such information should not be regarded as a representation or warranty, express or implied, by the Company or any other person that the objectives and plans of the Company will be achieved.


'/>"/>
SOURCE Ambry Genetics Corp.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. SemBioSys Genetics Inc. obtains up to $1.5 million in funding from AVAC
2. AgFeed Industries Enters Into Hog Genetic Program Arrangement with Hypor, the Pig Breeding Division of Hendrix Genetics B.V.
3. deCODE genetics Announces Webcast of Conference Call to Discuss Full-year 2008 Financial Results
4. SemBioSys Genetics Inc. Announces Clinical Results with Plant-Produced Insulin
5. Interleukin Genetics Reports Fourth Quarter and Year End 2008 Financial Results
6. Interleukin Genetics Receives Notification of Failure to Meet Continued Listing Standard Section 1003(a)(iii)
7. Matching Genetics, Technology and Management Practices Critical to Meeting Strong Demand for Agricultural Crops
8. Interleukin Genetics Appoints Todd Anthony Walker as Vice President, Marketing
9. HemoGenix(R), Inc Announces Implementation of ORF Genetics Human Growth Factors and Cytokines in All Human HALO(R) Assay Kits and Contract Research Services
10. Update: Georgia and North Carolina Teens Honored for Research in Biochemistry and Genetics in Nations Premier High School Science Competition
11. Interleukin Genetics Reports Third Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... 18, 2017 Applied BioMath ( www.appliedbiomath.com ... drug research and development, today announced that Dr. ... CEO of Applied BioMath, will present at the ... (BAGIM) Meeting on Thursday January 19, 2017 at ... , MA.   Dr. Burke,s talk "Quantitative Modeling and ...
(Date:1/18/2017)... ... 18, 2017 , ... Whitehouse Labs has furthered its efforts ... Inc. (AMRI), the scientific staff dedicated to Extractables / Leachables & Impurities has ... in 2017. Extractable & Leachable evaluations have become increasingly more vital to successful ...
(Date:1/18/2017)... ... January 18, 2017 , ... DrugDev customers are ... Ops Executives (Hyatt Regency Miami, January 24-26). DrugDev will join customers including Pfizer, ... such as trial performance metrics, patient enrollment diversity, protocol optimization, and global site ...
(Date:1/18/2017)... , Jan. 18, 2017 Shareholder rights ... investigation into whether the board members of CoLucid Pharmaceuticals, ... duties in connection with the proposed sale of the ... biopharmaceutical company that develops small molecules for the acute ... CoLucid announced it had signed a definitive merger agreement ...
Breaking Biology Technology:
(Date:1/11/2017)... , Jan. 11, 2017 Intoxalock, a ... with the release of its patent-pending calibration device. With ... reliably perform calibrations, securely upload data logs and process ... the customer. "Fighting drunk driving through the ... the public at large, but also for the customer ...
(Date:1/6/2017)... , Jan. 5, 2017  Delta ID Inc., ... iris scanning technology for automotive at CES® 2017. Delta ... GNTX ) to demonstrate the use of iris scanning ... and authenticate the driver in a car, and as ... the driving experience. Delta ID and Gentex ...
(Date:12/22/2016)... MOUNTAIN VIEW, Calif. , Dec. 20, 2016  As ... all levels, 23andMe, the leading personal genetics company, recently released ... Only Me . The book focuses on the topics ... the Next Generation Science Standards (NGSS) taught in elementary school ... the second in a series by illustrator Ariana Killoran ...
Breaking Biology News(10 mins):